Antibe Therapeutics (ATE) Trading 15.3% Higher

Antibe Therapeutics Inc (CVE:ATE)’s share price traded up 15.3% during trading on Monday . The stock traded as high as C$0.35 and last traded at C$0.34. 1,209,441 shares traded hands during mid-day trading, an increase of 113% from the average session volume of 568,696 shares. The stock had previously closed at C$0.30.

The company has a market cap of $71.72 million and a P/E ratio of -5.74. The company has a quick ratio of 2.10, a current ratio of 3.77 and a debt-to-equity ratio of 35.82.

Antibe Therapeutics (CVE:ATE) last released its earnings results on Friday, February 15th. The company reported C($0.01) EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of C($0.01). The business had revenue of C$2.50 million during the quarter, compared to analyst estimates of C$2.20 million. As a group, research analysts expect that Antibe Therapeutics Inc will post -0.0300000010169492 EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This story was first reported by Community Financial News and is the property of of Community Financial News. If you are accessing this story on another website, it was illegally stolen and republished in violation of United States and international copyright & trademark laws. The original version of this story can be viewed at

Antibe Therapeutics Company Profile (CVE:ATE)

Antibe Therapeutics Inc, a pharmaceutical development company, originates, develops, and out-licenses patent protected pharmaceuticals in Canada, Europe, and the United States. Its drugs are designed to prevent the gastrointestinal damage and bleeding caused by non-steroidal anti-inflammatory drugs. The company's lead compound is ATB-346, a hydrogen sulfide-releasing derivative of naproxen for treating rheumatoid arthritis, ankylosing spondylitis, and general pain reduction, which has completed Phase IIB gastrointestinal safety study.

See Also: What is a Stop Order?

Receive News & Ratings for Antibe Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antibe Therapeutics and related companies with's FREE daily email newsletter.


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit